Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of SH229 in Patients With HCV Infection

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
A total of 30 evaluable patients will be enrolled in this study. The planned dose levels are 400, 600, and 800 mg.
Epistemonikos ID: 15358247c1e01480edf491de204bbcd93f0284f7
First added on: Mar 23, 2020